Protea said its LAESI system is a next generation molecular imaging platform that directly analyses biological samples without the need to apply chemicals or introduce tags or tracers and enables two-dimensional and three-dimensional imaging, displaying the distribution of molecules in the samples.
Target: Protea Biosciences Group, Inc/ LAESI DP-1000 Instrument System
What we believe makes the LAESI DP-1000 unique is that it is a universal platform -- one that can be used to analyze all types of biological samples, including tissue biopsies, live cells, blood and other biofluids," said Protea CEO Steve Turner.
Ralph Paul, MPR Product Development's project manager for development of the LAESI DP-1000, attributes the success of this technology development to the close collaboration between Protea Biosciences, the laboratory of Dr.
Molecular information company Protea Biosciences Group (OTC BB:PRGB) disclosed on Thursday the sale of its LAESI DP-1000 Instrument System to Purdue University for an undisclosed amount.
The LAESI DP-1000 Instrument system will reportedly be used in Purdue's College of Agriculture, the Department of Botany and Plant Pathology for the molecular imaging of herbicide active ingredients and other related compounds to optimize herbicide applications and improve weed management.
Molecular information company Protea Biosciences Group (OTC BB:PRGB) revealed on Wednesday the sale of its LAESI DP-1000 Instrument System for direct molecular analysis to Princeton University.
The company said the LAESI DP-1000 Instrument System will be used in Princeton's Frick Chemistry Laboratory for the screening of microbial samples to identify new molecular entities for new antimicrobial therapeutics.
DP-1000 directly ionizes samples in a two-step process: laser ablation followed by electrospray ionization.
15 October 2014 - US molecular information company Protea Biosciences Group Inc (OTCBB:PRGB) said Wednesday that Princeton University had bought the company's LAESI
DP-1000 Instrument System designed for direct molecular analysis.
As part of the collaboration, the partners will use Protea's next-generation LAESI
direct molecular imaging technology to create molecular data profiles of cancer cells in tissue and biofluids to gain better insight into a cancer's origin.
Rapid (each analysis takes less than 2 seconds), sensitive and quantitative, LAESI
also provides 3 dimensional mapping of biomolecules through depth profiling and lateral imaging, Protea added.